Everest Medicines begins dosing in mRNA cancer vaccine trial

Everest Medicines has dosed the first subject with EVM16, the company’s personalised messenger ribonucleic acid (mRNA) cancer vaccine, in the first-in-human (FIH) trial, EVM16CX01.